In the Margins

Sequoia's Valeant bet hard lesson for investors

March 29, 2016

By MarketWatch

Sequoia Fund investors learned a hard lesson when the fund's investment in Valeant Pharmaceuticals went bad last year. "Bad doesn’t even begin to describe the situation for Sequoia, one of the most legendary mutual funds, which has seen its reputation torched by a bad bet on a controversial stock," writes MarketWatch's Chuck Jaffe in his latest column. Robert Goldfarb, CEO of adviser Ruane, Cunniff & Goldfarb and co-manager of Sequoia, resigned his fund duties last Wednesday. Read the original column from MarketWatch

 

 

Most Read

A Seat at the Table
Invesco Funds board finalizes succession plans

The Invesco Funds board will name Christopher Wilson vice chairman at its June meeting, making him the heir apparent to long-serving independent Chair Bruce Crockett. Crockett ...

Top of the Agenda - Compensation
Fund board comp moves up, as industry keeps changing

Analyzing mutual fund director compensation data is getting increasingly difficult as consolidation reshapes the mid-sized to large end of the market and a reduction in stand-alone ...

Top of the Agenda - Industry Groups
IDC's Amy Lancellotta to retire at year-end

Amy Lancellotta will retire from the Independent Directors Council at the end of this year after 13 years as managing director and a total of 30 ...